Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price target of $4.50. The stock closed at 72 cents on April 12.
Analyst Sa’ar Yaniv writes that Auris has multiple late-stage shots-on-goal in the coming 12-to-18 months.
“In our view, AM-111 and Keyzilen have compelling data from previous Phase 2 and Phase 3 studies that should enable successful completion of currently ongoing registrational studies,” he adds.
The AM-111 Phase 3 trial in hearing loss will have data in the third quarter this year and first half of 2018. Keyzilen will have data from a re-designed Phase 3 trial in the first quarter of 2018.
He said Auris’ AM-125, which could have expedited path to market, “represents a free call-option,” with Phase 1 data expected in the first half of 2018.
